United-Guardian (UG) Q4 2025 earnings summary

Executive summary

• Net sales declined 13% year-over-year to $10.5M in 2025, with net income falling to $2.1M from $3.25M in 2024.

• Earnings per share dropped to $0.46 from $0.71 year-over-year.

• Sales of pharmaceuticals and medical lubricants increased by 15% and 4%, respectively, offsetting some declines.

• Cosmetic ingredient sales were negatively impacted by distributor overstock, reduced global demand, and increased competition in China.

Financial highlights

• Net sales: $10,545,468 in 2025 vs. $12,181,971 in 2024.

• Net income: $2,105,738 in 2025 vs. $3,250,875 in 2024.

• Operating income: $2,243,348 in 2025 vs. $3,646,789 in 2024.

• Total assets: $13,108,579 at year-end 2025 vs. $13,797,335 at year-end 2024.

• Stockholders' equity: $11,232,012 at year-end 2025 vs. $11,882,866 at year-end 2024.

Outlook and guidance

• New marketing strategies and distribution agreements for cosmetic ingredients and pharmaceuticals are expected to drive future sales growth.

• Approval from two major pharmacy benefit managers for Renacidin® is anticipated to enhance long-term commercial growth.